Uncategorized
Brimonidine seen as promising treatment for geographic atrophy
CHICAGO — Neuroprotective brimonidine as a treatment for geographic atrophy is promising, William R. Freeman, MD, told colleagues at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.Freeman reported results of a phase 2 randomized clinical trial of brimonidine administered intravitreally using a 22-gauge insert placed in the eye that released brimonidine over a period of 6 months. Allergan sponsored the trial.